Blocking the survival of the nastiest by HSP90 inhibition

被引：9

作者：

Workman, Paul ^{[1
]}

Clarke, Paul A. ^{[1
]}

Al-Lazikani, Bissan ^{[1
]}

机构：

[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SW3 6JB, England

来源：

ONCOTARGET | 2016年 / 7卷 / 04期

关键词：

HSP90; CLONAL EVOLUTION; CANCER; RESISTANCE; THERAPY; MODELS;

D O I：

10.18632/oncotarget.6971

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

引用

页码：3658 / 3661

页数：4

共 50 条

[11] Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
Koay, Yen Chin
Wahyudi, Hendra
McAlpine, Shelli R.
CHEMISTRY-A EUROPEAN JOURNAL, 2016, 22 (51) : 18572 - 18582
[12] Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (hsp90) inhibition: a significant advance on current hsp90 chemotherapies
Koay, Yen Chin
McConnell, Jeanette R.
Wang, Yao
McAlpine, Shelli R.
RSC ADVANCES, 2015, 5 (73): : 59003 - 59013
[13] HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion
Taiyab, Aftab
Rao, Ch. Mohan
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2011, 1813 (01): : 213 - 221
[14] Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
Park, Sangkyu
Park, Jeong-A
Jeon, Jae-Hyung
Lee, Younghee
BIOMOLECULES & THERAPEUTICS, 2019, 27 (05) : 423 - 434
[15] Overview: Translating Hsp90 Biology into Hsp90 Drugs
Workman, Paul
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) : 297 - 300
[16] A comparison of Hsp90α and Hsp90β interactions with cochaperones and substrates
Taherian, Aliakbar
Krone, Patrick H.
Ovsenek, Nick
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 2008, 86 (01): : 37 - 45
[17] Hsp90 inhibition sensitizes DLBCL cells to cisplatin
Schmidt, Linnea
Issa, Issa Ismail
Haraldsdottir, Hulda
Hald, Jonas Laugard
Schmitz, Alexander
Due, Hanne
Dybkaer, Karen
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 431 - 440
[18] Inhibition of the oncogenic protein hsp90 by dietary quinones
Losso, Jack N.
Truax, Robert E.
Finley, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 121 - 121
[19] Hsp90 Inhibition Decreases Mitochondrial Protein Turnover
Margineantu, Daciana H.
Emerson, Christine B.
Diaz, Dolores
Hockenbery, David M.
PLOS ONE, 2007, 2 (10):
[20] Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
Kang, Junghee
Kamal, Adeela
Burrows, Francis J.
Evers, B. Mark
Chung, Dai H.
ANTICANCER RESEARCH, 2006, 26 (3A) : 1903 - 1908

← 1 2 3 4 5 →